目的 统计2020—2022年安徽省胸科医院抗结核药物使用情况并分析其变化趋势，为规范其合理应用提供一定参考。方法 对2020年1月—2022年12月安徽省胸科医院抗结核药物销售金额、用药频度（DDDs）、日均费用（DDC）以及金额排序/DDDs排序比（B/A）等进行统计分析。结果 2020—2022医院抗结核药物销售金额总体呈增长趋势，新型类抗结核药物销售金额2022年较2020年增幅333.43%，注射类降幅72.68%，贝达喹啉、注射用利奈唑胺、环丝氨酸、氯法齐明排名靠前，其中贝达喹啉连续2年销售金额排名第1位。DDDs每年总体基本稳定，排名靠前的为一线口服类抗结核药物：异烟肼、乙胺丁醇、吡嗪酰胺、利福平，2022年DDDs贝达喹啉排名第1位。利奈唑胺等40.00%抗结核药物DDC降低。每年一线口服类抗结核药物B/A均大于1，2022年B/A＞0.9的药物占比达60.00%。结论 安徽省胸科医院抗结核药物使用基本合理，仍然需要加强监督管理，减小耐药结核发生率。

Objective To investigate anti-tuberculosis drugs usage in Anhui Chest Hospital from 2020 to 2022 and analyze its change trend, so as to provide reference for regulating its rational application. Methods Annual consumption sums, DDDs, DDC, and the B/A of anti-tuberculosis drugs in Anhui Chest Hospital from January 2020 to December 2022 were analyzed statistically. Results From 2020 to 2022, consumption sums of anti-tuberculosis drugs in the hospital showed an overall increasing trend, and consumption sums of new anti-tuberculosis drugs increased by 333.43% in 2022 compared with 2020, while consumption sums of injection drugs decreased by 72.68%. Bedaquiline, linezolid for injection, cycloserine, and clofazimine ranked top, among which bedaquiline ranked first for two consecutive years. DDDs were basically stable every year, and the top ones were first-line oral anti-tuberculosis drugs, such as isoniazid, ethambutol, pyrazinamide, and rifampicin. In 2022, bedaquiline ranked first. DDC of 40.00% anti-tuberculosis drugs such as linezolid decreased. The B/A of first-line oral anti-tuberculosis drugs was greater than 1. In 2022, drugs with B/A＞0.9 accounted for 60.00%. Conclusion The use of anti-tuberculosis drugs in Anhui Chest Hospital was basically reasonable, and supervision and management should be strengthened to reduce the incidence of anti-tuberculosis drugs.

R978.3